Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    8
    ...
ATC Name B/G Ingredients Dosage Form Price
L01FX28 COLUMVI BioTech Glofitamab - 2.5mg/2.5ml 2.5mg/2.5ml Injectable concentrate for solution 87,389,307 L.L
C07AB07 CONCOR COR B Bisoprolol fumarate - 2.5mg 2.5mg Tablet, film coated 488,906 L.L
J01XB01 COLISTIN HIKMA G Colistimethate Sodium - 1MIU 1MIU Injectable powder for solution, Inhalation powder 903,062 L.L
J01XB01 COLISTIN/NORMA G Colistimethate Sodium - 1MIU 1MIU Injectable solution 872,154 L.L
B03BA01 CYNOVIT-JULPHAR G Vitamin B12 - 1mg/ml 1mg/ml Injectable solution 167,980 L.L
L01CA02 CELLCRISTIN G Vincristine sulfate - 1mg/ml 1mg/ml Injectable solution 1,443,287 L.L
A06AX05 CONSTIPRIDE G Prucalopride succinate - 1mg 1mg Tablet, film coated 2,015,764 L.L
A03FA08 CINITREX G Cinitapride - 1mg 1mg Tablet 636,981 L.L
M04AC01 COLCHICINE OPOCALCIUM B Colchicine - 1mg 1mg Tablet, scored 288,926 L.L
M04AC01 COLCHICINE BENTA G Colchicine - 1mg 1mg Tablet, film coated 332,761 L.L
M04AC01 COLCHICINE SEID G Colchicine - 1mg 1mg Tablet 382,995 L.L
J01CR02 CURAM G Amoxicillin (trihydrate) - 875mg, Clavulanic Acid (potassium) - 125mg 1g Tablet, film coated 541,236 L.L
J01DB04 CEFAZOL IM/IV G Cefazolin (sodium) - 1g 1g Injectable powder 5,375,370 L.L
J01DB04 CEFAZOLIN PANPHARMA G Cefazolin (sodium) - 1g 1g Injectable powder for solution 5,521,849 L.L
J01DB04 CEFAZOLINA G Cefazolin (sodium) - 1g 1g Injectable powder for solution 18,574,396 L.L
J01DD01 CEFOTAX G Cefotaxime (sodium) - 1g 1g Injectable lyophilised powder for solution+diluent 217,702 L.L
J01DD01 CEFOTAXIME PANPHARMA G Cefotaxime (sodium) - 1g 1g Injectable lyophilised powder for solution 6,127,922 L.L
J01DD01 CLAFOCARE G Cefotaxime (sodium) - 1g 1g Injectable powder for solution 8,031,731 L.L
J01DD02 CEFTAZIDIME PANPHARMA G Ceftazidime (pentahydrate) - 1g 1g Injectable powder for solution 3,300,477 L.L
J01DD04 CEFAXONE G Ceftriaxone - 1g 1g Injectable powder 403,153 L.L
J01DD04 CEFAXONE IM/IV G Ceftriaxone - 1g 1g Injectable lyophilised powder for solution 3,628,375 L.L
J01DD04 CEFAXONE IV G Ceftriaxone - 1g 1g Injectable lyophilised powder for solution+diluent 403,153 L.L
J01DD04 CEFTRIAXONE PANPHARMA G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution 5,933,065 L.L
J01DD07 CEFIZOX B Ceftizoxime (sodium) - 1g 1g Injectable powder for solution 788,836 L.L
J01DE01 CEFEPIME LDP LABORATORIOS TORLAN G Cefepime - 1g 1g Injectable powder for solution 5,933,065 L.L
J01DE01 CEFEPIME PANPHARMA G Cefepime - 1g 1g Injectable powder for solution 5,933,065 L.L
N06BA04 CONCERTA B Methylphenidate HCl - 18mg 18mg Tablet, extended release 3,133,841 L.L
A03AX COLPERMIN B Pepermint oil - 187mg 187mg Capsule, delayed release 632,950 L.L
C09CA06 CANDESARTAN BIOGARAN G Candesartan cilexetil - 16mg 16mg Tablet, scored 434,061 L.L
L01EJ01 CELEZON G Ruxolitinib - 15mg 15mg Tablet 188,515,591 L.L
    ...
    8
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025